ArticleCommunications biology2025
Therapeutic targeting SPI1 in combination with erastin promotes ferroptosis in ccRCC.
Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- PYCR1 modulates ferroptosis and malignant phenotypes of clear cell renal cell carcinoma through proline biosynthesis.Molecular biology reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clear cell renal cell carcinoma is the most common renal cell carcinoma subtype with a poor prognosis. The SPI1/Pu.1, which encodes a member of the E26-transformation-specific family of transcription factors, is highly expressed and associated with poor prognosis in renal cell carcinoma. Ferroptosis, a form of cell death distinct from apoptosis, pyroptosis, and necrosis, is characterized by iron accumulation and lipid peroxidation. Although the role of SPI1 in renal cell carcinoma is recognized, its relationship with ferroptosis remains unclear. In this study, we demonstrate that SPI1 is differentially overexpressed in renal cell carcinoma and associated with unfavorable prognosis. We also show that knockdown of SPI1 enhances erastin-induced ferroptosis. Furthermore, combining EZH2 inhibitors with erastin similarly promotes ferroptosis in renal cancer cells. Mechanistically, SPI1 transcriptionally suppresses ACSL4 expression through the EZH2/H3K27me3 pathway, leading to inhibition of intracellular lipid peroxidation. Thus, SPI1 knockdown synergizes with erastin to promote lipid peroxidation and ferroptosis, suggesting that targeting SPI1 may represent a promising therapeutic strategy for renal cell carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.